Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
8Customers
2Debt Items
6Related Chains
Source-Backed Evidence Depth
BridgeBio Oncology Therapeutics, Inc. (BBOT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
1Distinct source URLs
4High confidence
0.731Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
BridgeBio Oncology Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
LAWRENCE-LIVERMORE-NATIONAL-SECURITY-LLC
LAWRENCE-LIVERMORE-NATIONAL-SECURITY-LLC
92%
In May 2018, the Company entered into a cooperative research and development agreement ("LLNS CRADA") with Lawrence Livermore National Security, LLC ("LLNS") to explore new knowledge therapeutics pos…
Reciprocal relationship from BBIO graph: Reciprocal relationship from BBOT graph: Reciprocal relationship from BBIO graph: quity financing with external investors to accelerate the development of its…
Reciprocal relationship from BBIO graph: Reciprocal relationship from BBOT graph: de 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco, California. de-SPAC Transaction On F…
de 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco, California. de-SPAC Transaction On February 28, 2025, TheRas Inc. (“Legacy BBOT”), a privately held Delaware corporati…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
merged with and into Legacy BBOT, with Legacy BBOT surviving the merger as a wholly-owned subsidiary of Helix (“Merger”). In connection with the Merger, Helix changed its name to BridgeBio Oncology T…
HELIX-ACQUISITION-CORP
HELIX-ACQUISITION-CORP
62%
those that we currently anticipate will be required to complete clinical development and obtain regulatory approval of one or more product candidates, or if we experience significant delays in our pr…
HELIX-II-MERGER-SUB-INC
HELIX-II-MERGER-SUB-INC
62%
de 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco, California. de-SPAC Transaction On February 28, 2025, TheRas Inc. (“Legacy BBOT”), a privately held Delaware corporati…
LAWRENCE-LIVERMORE-NATIONAL-SECURITY-LLC
LAWRENCE-LIVERMORE-NATIONAL-SECURITY-LLC
62%
inancing activities of $0.3 million for the three months ended March 31, 2026 included $0.4 million in proceeds from option exercises, offset by $0.1 million in payments of deferred transaction costs…
LEIDOS-BIOMEDICAL-RESEARCH-INC
LEIDOS-BIOMEDICAL-RESEARCH-INC
62%
inancing activities of $0.3 million for the three months ended March 31, 2026 included $0.4 million in proceeds from option exercises, offset by $0.1 million in payments of deferred transaction costs…
TRANSACTIONS-BRIDGEBIO-PHARMA-INC
TRANSACTIONS-BRIDGEBIO-PHARMA-INC
62%
de 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco, California. de-SPAC Transaction On February 28, 2025, TheRas Inc. (“Legacy BBOT”), a privately held Delaware corporati…
BridgeBio Oncology Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BBOT-DEBT-14223
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
BBOT-DEBT
Debt stack $2.6M
90%
Market cache reports total debt of $2.6M.
BridgeBio Oncology Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BridgeBio Oncology Therapeutics, Inc..
BridgeBio Oncology Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
BBOT-OWNER-CORMORANT-ASSET-MANAGEMENT-LP
Cormorant Asset Management, LP
90%
13F overlay lists Cormorant Asset Management, LP as top holder; 67 tracked holders.
BridgeBio Oncology Therapeutics, Inc. Extended Supply Chain Network
